Axsome Therapeutics Secures Extended Market Exclusivity for SUNOSI

Axsome Therapeutics, Inc. Has successfully defended its market exclusivity for SUNOSI® (solriamfetol), a drug used to treat excessive daytime sleepiness, through a settlement agreement with Alkem Laboratories Ltd. This agreement effectively prevents the introduction of a generic version of the drug until at least 2040, preserving Axsome’s revenue stream for the foreseeable future.

Settlement Details and Timeline

The settlement, announced on February 17, 2026, resolves patent litigation stemming from Alkem’s attempt to market a generic version of SUNOSI. Under the terms of the agreement, Alkem will be granted a license to sell its generic solriamfetol beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI. If pediatric exclusivity is not granted, the generic can be launched on or after March 1, 2040. The agreement is subject to FDA approval and standard conditions for such settlements.

Patent Litigation and Market Impact

Axsome initiated patent infringement lawsuits against Alkem to protect its intellectual property rights for SUNOSI. This legal strategy reflects a broader trend within the pharmaceutical industry to extend market exclusivity beyond initial patent expiration dates. The extended exclusivity is particularly significant given SUNOSI’s contribution to Axsome’s revenue.

Regulatory Review

As required by law, Axsome and Alkem will submit the settlement agreement to the U.S. Federal Trade Commission (FTC) and the U.S. Department of Justice for review. This is standard procedure to ensure the agreement does not violate antitrust laws, particularly those concerning “pay-for-delay” settlements.

Ongoing Litigation

Axsome continues to pursue similar patent litigation against other parties seeking to develop generic versions of SUNOSI. This ongoing legal activity underscores the company’s commitment to protecting its market position.

About SUNOSI (solriamfetol)

SUNOSI is a medication approved for the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. It works by increasing dopamine and norepinephrine levels in the brain, promoting wakefulness.

Key Takeaways

• Axsome Therapeutics has secured market exclusivity for SUNOSI until at least 2040.
• The agreement with Alkem Laboratories Ltd. Resolves ongoing patent litigation.
• The settlement is subject to regulatory review by the FTC and DOJ.
• Axsome continues to defend its patent rights against other potential generic manufacturers.

This outcome highlights the complex interplay between patent law, pharmaceutical innovation and market competition. The extended exclusivity period for SUNOSI will likely impact the availability and pricing of the medication, potentially affecting healthcare costs for patients and insurers.

Sources:

Law360, Yahoo Finance, Legal News Feed, Investing News